Want to see ORKA full AI Analyst Report?
Oruka Therapeutics (ORKA) Financial Statements
Oruka Therapeutics Financial Overview
Oruka Therapeutics's market cap is currently $6.41B. The company's EPS TTM is $-2.47; its P/E ratio is -39.22; and it has a dividend yield of 64.52%. Oruka Therapeutics is scheduled to report earnings on November 18, 2026, and the estimated EPS forecast is $-0.60. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -83.00K | $ -27.00K | $ -114.00K | $ -91.00K | $ -93.00K |
| Operating Income | $ -122.05M | $ -88.12M | $ -9.84M | $ -19.34M | $ -9.77M |
| EBITDA | $ -105.35M | $ -82.23M | $ -9.81M | $ -19.23M | $ -9.64M |
| Net Income | $ -105.43M | $ -83.72M | $ -9.93M | $ -19.32M | $ -9.74M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 337.04M | $ 375.65M | $ 42.45M | $ 53.36M | $ 49.07M |
| Total Assets | $ 488.62M | $ 396.02M | $ 43.09M | $ 54.92M | $ 50.43M |
| Total Debt | $ 1.93M | $ 968.00K | $ 383.00K | $ 483.00K | $ 450.00K |
| Net Debt | $ -45.00M | $ -60.61M | $ -42.06M | $ -52.88M | $ -48.62M |
| Total Liabilities | $ 16.69M | $ 13.80M | $ 1.41M | $ 3.88M | $ 3.91M |
| Stockholders' Equity | $ 471.93M | $ 382.22M | $ 41.67M | $ 51.04M | $ 46.52M |
| Cash Flow | |||||
| Free Cash Flow | $ -88.42M | $ -58.03M | $ -10.91M | $ -18.80M | $ -7.74M |
| Operating Cash Flow | $ -88.21M | $ -57.84M | $ -10.91M | $ -18.76M | $ -7.72M |
| Investing Cash Flow | $ -96.75M | $ -330.13M | $ -2.00K | $ -43.00K | $ -19.00K |
| Financing Cash Flow | $ 170.31M | $ 449.54M | $ 0.00 | $ 23.09M | $ 48.45M |
Currency in USD